BioAtla, Inc. (BCAB) Stock Analysis & Investment Frameworks
BioAtla, Inc. (BCAB) stock analysis on Invetso. Review BioAtla, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
BioAtla, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
BioAtla, Inc. Key Financial Metrics
- Market Cap: $2.88M
- Revenue: $2.00M
- ROE: 89.25%
- ROIC: 323.03%
- Dividend Yield: N/A
About BioAtla, Inc.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
BioAtla, Inc. Investment Frameworks
Invetso analyzes BioAtla, Inc. (BCAB) across the following frameworks:
- BioAtla, Inc. 10Y Growth Potential
- BioAtla, Inc. Scenario Analysis
- BioAtla, Inc. Risks & Opportunities
- BioAtla, Inc. Economic Moat
- BioAtla, Inc. Business Model
- BioAtla, Inc. Management
- BioAtla, Inc. SWOT Analysis
- BioAtla, Inc. Porter's 5 Forces
- BioAtla, Inc. PESTLE Analysis
- BioAtla, Inc. ESG Analysis